Typically, patients and their fitness to undergo relatively aggressive therapies is determined largely by clinical gestalt, and prognostic features limited to specific features of a patients pathology (for example Ki67 index in meningioma or IDH status in gliomas). The gene discussed is MKI67; the disease is central nervous system cancer.